Serotonergic response to stress: A protective factor against abnormal dopaminergic reactivity in schizophrenia?

European Psychiatry

Volumn 22, Issue 6, 2007, Pages 362-364

  Brunelin, Jerome ^a,b,c,d   D'amato, Thierry ^a,b,c   Os, Jim van ^d,e   Dalery, Jean ^a,b,c   Suaud Chagny, Marie Françoise ^a,b,c   Saoud, Mohamed ^a,b,c  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c IFNL   (France)

^d Department of Psychiatry and Psychology   (Netherlands)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Prevention; Schizophrenia; Vulnerability stress model

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; DEOXYGLUCOSE; DOPAMINE; FLUPENTIXOL; HOMOVANILLIC ACID; OLANZAPINE; PLACEBO; RISPERIDONE; SEROTONIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIBLING; STRESS;

ADULT; ANTIMETABOLITES; AROUSAL; CROSS-OVER STUDIES; DEOXYGLUCOSE; DOPAMINE; DOUBLE-BLIND METHOD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; REFERENCE VALUES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SIBLINGS; SOCIAL ENVIRONMENT; STRESS;

EID: 34548622182     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2007.01.1219     Document Type: Article

References (15)

1. 123I]iodobenzamide. Biol Psychiatry 55 10 (2004) 1001-1006
2. Amargos-Bosch M., Lopez-Gil X., Artigas F., and Adell A. Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int J Neuropsychopharmacol 15 (2005) 1-9
3. Amin F., Davidson M., and Davis K.L. Homovanillic acid measurement in clinical research: a review of methodology. Schizophr Bull 18 (1992) 123-148
4. Breier A., Davis O.R., and Buchanan R.W. Alprazolam attenuates metabolic stress-induced neuroendocrine and behavioral effects in humans. Psychopharmacology (Berl) 104 4 (1991) 479-484
5. Cornblatt B., Lencz T., and Obuchowski M. The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr Res 54 1-2 (2002) 177-186
6. Elman I., Lukas S., Shoaf S.E., Rott D., Adler C., and Breier A. Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia. J Psychopharmacol 17 3 (2003) 317-323
7. Gottesman II., and Bertelsen A. Confirming unexpressed genotypes for schizophrenia. Risks in the offspring of Fischer's Danish identical and fraternal discordant twins. Arch Gen Psychiatry 46 (1989) 867-872
8. Kopin I.J., Bankiewicz K.S., and Harvey-White J. Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: validation in monkeys treated with MPTP. Neuropsychopharmacology 1 (1988) 119-125
9. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., et al. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44 11 (1998) 1099-1117
10. Marcelis M., Cavalier E., Gielen J., Delespaul P., and Van Os J. Abnormal response to metabolic stress in schizophrenia: marker of vulnerability or acquired sensitization?. Psychol Med 34 6 (2004) 1103-1111
11. Myin-Germeys I., Marcelis M., Krabbendam L., Delespaul P., and van Os J. Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry 58 2 (2005) 105-110
12. Saoud M., d'Amato T., Gutknecht C., Triboulet P., Bertaud J.P., Marie-Cardine M., et al. Neuropsychological deficit in siblings discordant for schizophrenia. Schizophr Bull 26 4 (2000) 893-902
13. Spring B., and Zubin J. Attention and information-processing as indicators of vulnerability to schizophrenic episodes. In: Wynne L.C., Cromwell R.L., and Matthysse S. (Eds). The nature of schizophrenia: approaches to research and treatment (1978), Wiley, New York 366-375
14. van Os J., and Marcelis M. The ecogenetics of schizophrenia: a review. Schizophr Res 32 2 (1998) 127-135
15. Yamamoto B.K., Pehek E.A., and Meltzer H.Y. Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55 B (1994) 8-14